Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13057129 | 0.84 | FOLH1 (0.51) | FOLH1ADRA1ASIRT5KDM4EMAPK1 | |
| SCHEMBL25548906 | 0.84 | FOLH1 (0.51) | FOLH1ADRA1ASIRT5KDM4EMAPK1 | |
| SCHEMBL25548851 | 0.81 | FOLH1 (0.60) | FOLH1GNPAT | |
| SCHEMBL29431224 | 0.80 | KMT2A (0.42) | SIRT2SIRT1SIRT3 | |
| SCHEMBL24802697 | 0.79 | GNPAT (0.41) | FOLH1GNPATSIRT2SIRT1SIRT3 | |
| SCHEMBL20341086 | 0.79 | FOLH1 (0.70) | FOLH1ADRA1ASIRT5GNPAT | |
| SCHEMBL13888703 | 0.78 | FOLH1 (0.54) | FOLH1ADRA1ASIRT5KDM4EMAPK1 | |
| SCHEMBL25550094 | 0.78 | SIRT5 (0.55) | FOLH1ADRA1ASIRT5GNPATKDM4E | |
| SCHEMBL24170246 | 0.78 | FOLH1 (0.47) | FOLH1ADRA1ASIRT5KDM4EMAPK1 | |
| SCHEMBL3728197 | 0.78 | CAPN1 (0.46) | SIRT5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2022-12-29 | — | — | US | disclosed |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2021-11-16 | — | — | US | disclosed |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | FOLH1 202/4885ADRA1A 2960/4885SIRT5 1691/4885 |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | GCG, GLP1R, GHSR | FOLH1 237/4885ADRA1A 3045/4885SIRT5 3718/4885 |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, GLP1R, INSR | FOLH1 671/4885ADRA1A 380/4885SIRT5 4728/4885 |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | FOLH1 851/4885ADRA1A 252/4885SIRT5 4497/4885 |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, GCGR | FOLH1 190/4885ADRA1A 1552/4885SIRT5 2662/4885 |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, INSR, GLP1R | FOLH1 767/4885ADRA1A 284/4885SIRT5 4681/4885 |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, GCG, HBB | FOLH1 162/4885ADRA1A 3499/4885SIRT5 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.